Literature DB >> 10485273

Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines.

C Gabay1, H Ben-Bassat, M Schlesinger, R Laskov.   

Abstract

Three established Burkitt's lymphoma (BL) cell lines (Daudi, Raji and DG-75) and three B-non-Hodgkin's lymphoma (B-NHL) of other types (Pfeiffer, Farage and Toledo) were analyzed with respect to the presence of somatic point mutations in their rearranged immunoglobulin Vkappa genes. Two of the Vkappa sequences of BL and two of those of the B-NHL were heavily mutated (up to 11%), when compared with their closest germline variable region counterparts ("clonal mutations"). Only one of the six cell lines contained an unmutated germline Vkappa sequence. The clonal mutations have features characteristic of the mutation machinery operating in the course of the T-dependent immune response, such as a preference of mutations in purine bases, more transitions than transversions and targeting to CDR and to known "hotspot" motifs. Sequence variations among different Vkappa PCR clones isolated from each of the cell lines ("intraclonal mutations") showed that the Vkappa of Toledo exhibited about 5-fold higher mutation frequency (MF) than the background level of Taq polymerase error (approximately 0.12% mut/bp). Similarly, the MF of Vkappa of two of the BL cell lines was 3-4-fold higher than the Taq polymerase misincorporation rate. In contrast, the mutation frequencies of the Vkappa of DG-75, Farage and Pfeiffer did not significantly exceed the level of Taq polymerase error. Our combined results show that 5 out of the 6 B-cell lines studied originated from B-cells that have already somatically mutated in vivo their rearranged Vkappa genes. Moreover, two of the Burkitt's and one of the B-NHL cell lines exhibit intraclonal variation indicating that the process of somatic hypermutation continued following the neoplastic event, either in vivo or in culture. These results are in accord with the presumed origin of the majority of the BL and some types of the B-NHL, from centrocytes or centroblasts of the germinal centers in which the process of somatic hypermutation is taking place.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485273     DOI: 10.1111/j.1600-0609.1999.tb01766.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  10 in total

1.  Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.

Authors:  Sajal K Ghosh; Susan P Perrine; Robert M Williams; Douglas V Faller
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).

Authors:  Michael T McCabe; Alan P Graves; Gopinath Ganji; Elsie Diaz; Wendy S Halsey; Yong Jiang; Kimberly N Smitheman; Heidi M Ott; Melissa B Pappalardi; Kimberly E Allen; Stephanie B Chen; Anthony Della Pietra; Edward Dul; Ashley M Hughes; Seth A Gilbert; Sara H Thrall; Peter J Tummino; Ryan G Kruger; Martin Brandt; Benjamin Schwartz; Caretha L Creasy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

3.  Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity.

Authors:  Shelley E Ackerman; Cecelia I Pearson; Joshua D Gregorio; Joseph C Gonzalez; Justin A Kenkel; Felix J Hartmann; Angela Luo; Po Y Ho; Heidi LeBlanc; Lisa K Blum; Samuel C Kimmey; Andrew Luo; Murray L Nguyen; Jason C Paik; Lauren Y Sheu; Benjamin Ackerman; Arthur Lee; Hai Li; Jennifer Melrose; Richard P Laura; Vishnu C Ramani; Karla A Henning; David Y Jackson; Brian S Safina; Grant Yonehiro; Bruce H Devens; Yaron Carmi; Steven J Chapin; Sean C Bendall; Marcin Kowanetz; David Dornan; Edgar G Engleman; Michael N Alonso
Journal:  Nat Cancer       Date:  2020-12-07

4.  The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Authors:  Stephen E Spurgeon; Greg Coffey; Luke B Fletcher; Russell Burke; Jeffrey W Tyner; Brian J Druker; Andreas Betz; Francis DeGuzman; Yvonne Pak; Dale Baker; Anjali Pandey; Stanley J Hollenbach; Uma Sinha; Marc M Loriaux
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

5.  A proapoptotic signaling pathway involving RasGRP, Erk, and Bim in B cells.

Authors:  Stacey L Stang; Ana Lopez-Campistrous; Xiaohua Song; Nancy A Dower; Peter M Blumberg; Paul A Wender; James C Stone
Journal:  Exp Hematol       Date:  2009-01       Impact factor: 3.084

6.  Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells.

Authors:  Kathleen Richter; Sukhdev Brar; Madhumita Ray; Prapaporn Pisitkun; Silvia Bolland; Laurent Verkoczy; Marilyn Diaz
Journal:  J Biol Chem       Date:  2009-09-04       Impact factor: 5.157

7.  Telomere homolog oligonucleotides induce apoptosis in malignant but not in normal lymphoid cells: mechanism and therapeutic potential.

Authors:  Harold O Longe; Paul B Romesser; Andrew M Rankin; Douglas V Faller; Mark S Eller; Barbara A Gilchrest; Gerald V Denis
Journal:  Int J Cancer       Date:  2009-01-15       Impact factor: 7.396

8.  Kaposi's sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis.

Authors:  Guillaume Suffert; Georg Malterer; Jean Hausser; Johanna Viiliäinen; Aurélie Fender; Maud Contrant; Tomi Ivacevic; Vladimir Benes; Frédéric Gros; Olivier Voinnet; Mihaela Zavolan; Päivi M Ojala; Juergen G Haas; Sébastien Pfeffer
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

9.  Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.

Authors:  Victoria M Smith; Anna Dietz; Kristina Henz; Daniela Bruecher; Ross Jackson; Lisa Kowald; Sjoerd J L van Wijk; Sandrine Jayne; Salvador Macip; Simone Fulda; Martin J S Dyer; Meike Vogler
Journal:  Haematologica       Date:  2019-10-10       Impact factor: 9.941

10.  A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia.

Authors:  Bora E Baysal
Journal:  PLoS One       Date:  2007-05-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.